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The presentation of exogenous protein antigens in a major histocompatibility complex class I–
restricted fashion to CD8
 
 
 
 T cells is called cross-presentation. We demonstrate that cross-
presentation of soluble viral antigens (derived from hepatitis C virus [HCV], hepatitis B virus 
[HBV], or human immunodeficiency virus) to specific CD8
 
 
 
 T cell clones is dramatically 
improved when antigen-presenting dendritic cells (DCs) are pulsed with the antigen in the 
presence of chloroquine or ammonium chloride, which reduce acidification of the endocytic 
system. The export of soluble antigen into the cytosol is considerably higher in chloroquine-
treated than in untreated DCs, as detected by confocal microscopy of cultured cells and 
Western blot analysis comparing endocytic and cytosolic fractions. To pursue our findings in 
an in vivo setting, we boosted groups of HBV vaccine responder individuals with a further 
dose of hepatitis B envelope protein vaccine with or without a single dose of chloroquine. 
Although all individuals showed a boost in antibody titers to HBV, six of nine individuals 
who were administered chloroquine showed a substantial CD8
 
 
 
 T cell response to HBV 
antigen, whereas zero of eight without chloroquine lacked a CD8 response. Our results 
suggest that chloroquine treatment improves CD8 immunity during vaccination.
 
MHC class I molecules generally present pep-
tides derived from endogenous antigens (i.e.,
viral,  tumor, or self-proteins) that have been
synthesized and processed within cells (1). How-
ever, some specialized APCs are capable of pre-
senting exogenous antigens to CD8
 
 
 
 T cells
(2–15). This process, termed cross-presentation
(16), is primarily performed by DCs in vivo (2,
17–20). In the steady state, cross-presentation by
immature (i) DCs leads to cross-tolerance (21–
25). In contrast, upon DC maturation by a vari-
ety of innate immunity signals, cross-presentation
primes CD8
 
 
 
 T cell responses against tumor,
virus-infected, apoptotic cells, or those patho-
gens that do not infect or functionally impair
APCs (11–15, 23–32). Two independent, but
not necessarily exclusive, pathways have been
proposed for explaining cross-presentation, but
the revised model of the cytosolic pathway
seems to reconcile the endosomal and the con-
ventional cytosolic models (11–15, 28). Accord-
ing to this model, phagosomes would fuse with
the ER membrane, thus acquiring both ER
molecules (i.e., the protein translocation channel
Sec61 and the transporters associated to antigen
presentation [TAP]) and, ultimately, the capacity
to function as organelles autonomously cross-
presenting exogenous antigens via a phagosomal
proteasome-/TAP-dependent route (33–36). Al-
though particulate antigens (i.e., those associated
with pathogens, immune complexes, apoptotic
cells, virus-infected cells, or antigen/heat shock
protein complexes [11, 12, 14, 15, 28, 37]) are
efficiently cross-presented via this ER-like pha-
gosomal pathway, cross-presentation of soluble
antigens is considerably less efficient (11, 12, 14,
15, 28, 38–40), despite their ability to access
macropinocytotic compartments with similar
ER-like characteristics (33, 41).
We demonstrate that by inhibiting endoso-
mal acidification with lysosomotropic agents
(i.e., chloroquine or NH
 
4
 
Cl), the efficiency of
cross-presentation is substantially improved in
vitro via an increased export of soluble antigens
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into the cytosol of DCs. The importance of these results en-
couraged us to carry out an in vivo study, which proved that a
short course of chloroquine treatment followed by a booster
dose of anti–hepatitis B virus (HBV) vaccine enhanced anti-
gen-specific CD8
 
 
 
 T cell responses in HBV-vaccinated
healthy individuals. Our data imply that this well-tolerated an-
timalarial drug can be used for the design of innovative vac-
cines aimed at eliciting protective CD8 immunity in humans.
 
RESULTS
Cross-presentation of soluble antigens is up-regulated 
by inhibitors of intravesicular acidification in vitro
 
We devised a system in which human HLA-A2
 
 
 
 iDCs
cross-presented soluble r nonstructural 3 antigen (rNS3Ag)
of hepatitis C virus (HCV) to an HLA-A2–restricted
NS3
 
1406–1415
 
-specific CD8
 
 
 
 T cell clone (Fig. 1). Cross-pre-
sentation of soluble NS3Ag (Fig. 1, A and B), but not
NS3
 
1406–1415
 
 peptide presentation (Fig. 1 F), was drastically
blocked by lactacystin, a potent proteasome inhibitor (11–
15, 28). This supports the idea that soluble NS3Ag cross-
presentation requires proteasome-dependent processing.
Surprisingly, cross-presentation efficiency improved when
iDCs were pulsed in the presence of chloroquine (Fig. 1,
A–C) or NH
 
4
 
Cl (not depicted), whereas the antigen presenta-
tion to CD4
 
 
 
 T cells was strongly inhibited (Fig. 1 E). Nota-
bly, lactacystin drastically blocked cross-presentation of solu-
ble antigens, even in the presence of chloroquine (Fig. 1, A
and B). Chloroquine did not affect the peptide presentation
of DCs to either CD8
 
 
 
 or CD4
 
 
 
 T cells (Fig. 1, F and G),
ruling out the possibility that it improved cross-presentation
by up-regulating the costimulatory capacities of DCs. Both
chloroquine and NH
 
4
 
Cl are lysosomotropic agents that dif-
fuse across membranes and inhibit intravesicular acidifica-
tion, which is critical to activate several acid proteases that
induce proteolysis of antigens in the endocytic compart-
 
Figure 1. Cross-presentation efficiency is dependent on the 
inhibition of antigen degradation. 
 
(A) FC analysis of an HLA-A2–
restricted NS3
 
1406–1415
 
-specific CD8
 
 
 
 T cell clone producing IFN-
 
 
 
 in 
response to NS3Ag cross-presented by HLA-A2
 
 
 
 iDCs, in the presence 
or absence of the indicated compounds. Dot plots show double CD8 
and IFN-
 
 
 
 staining. Results are expressed as percentages of cells and 
are indicated in each quadrant. One representative out of six different 
experiments is shown. (B) NS3Ag cross-presentation after 12 h of pulsing 
by six independent HLA-A2
 
 
 
 iDC populations to an NS3
 
1406–1415
 
-specific 
CD8 clone (mean 
 
 
 
 SD), in the absence (diamonds) or presence of chloroquine 
(triangles), leupeptin (squares), or lactacystin (circles). *, P 
 
  
 
0.0001 in 
the presence versus absence of chloroquine. (C) Chase time of 50 
 
 
 
g/ml 
NS3Ag cross-presentation after 30 min of pulsing by six independent 
iDC populations (mean 
 
 
 
 SD), in the presence (triangles) or absence 
(diamonds) of chloroquine. *, P 
 
  
 
0.001 and **, P 
 
 
 
 0.0001 in the presence 
versus absence of chloroquine. (D) NS3Ag (closed diamonds), NS3Ag 
 
 
 
 
chloroquine (triangles), or peptide (open diamonds) presentation by 
three independent HLA-A2
 
 
 
 EBV–B cells to an NS3
 
1406–1415
 
-specific CD8 
clone (mean 
 
 
 
 SD). (E) Presentation of NS3Ag (*, P 
 
  
 
0.0001 in the 
presence versus absence of chloroquine) by four independent DC 
populations to an NS3
 
1241–1260
 
-specific CD4 T cell clone (mean 
 
 
 
 SD), 
in the presence (triangles) or absence (diamonds) of chloroquine. 
(F and G) Presentation of the indicated peptides to the NS3
 
1406–1415
 
-
specific CD8 clone (F) or the NS3
 
1241–1260
 
-specific CD4 T cell clone (G) 
in the absence (diamonds) or presence of chloroquine (triangles) or 
lactacystin (circles).
Figure 2. Efficient direct presentation of endogenous NS3Ag. FC 
analysis of 2   104 HLA-A2  NS31406–1415-specific CD8  T cell clones 
producing IFN-  in response to endogenous NS3Ag directly presented by 
2   104 autologous EBV–B cells that had been infected by either 5 PFU/cell 
of WT VV or NS3Ag-expressing VV (VV-NS3), in the presence or absence of 
lactacystin (lacta.) or chloroquine (chlor.). Dot plots show IFN-  staining. 
Results are expressed as percentages of cells and are indicated in each 
quadrant. One representative out of three different experiments is shown. 
SSC, side scatter. 
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ments (14, 42). Furthermore, it has been reported that chlo-
roquine causes direct lysosomal membrane permeabilization,
with the subsequent release of lysosomal products (i.e., ca-
thepsins) from the lysosomal lumen into the cytosol (43). In
contrast, only a slight, or no, improvement in cross-presen-
tation was observed with compounds that inhibit various
proteases without interfering with the pH level, such as leu-
peptin (Fig. 1 B), pepstatin A, EDTA, or peflabloc (unpub-
lished data). Further studies are required to verify whether
this finding is caused by the protease inhibitors used not be-
ing readily membrane permeable (as opposed to chloroquine
and NH
 
4
 
Cl), which may thus cause them to accumulate at
lower concentrations inside cells. Nonprofessional APCs,
such as autologous EBV-transformed B cells (EBV–B cells;
Fig. 1 D), were unable to cross-present even in the presence
of chloroquine. In addition, EBV–B cells, but not iDCs,
were unable to internalize 40-kD FITC-conjugated (FITC)–
dextran, which is known to be efficiently captured via man-
Figure 3. Cross-presentation and its improvement are restricted 
to iDCs. (A) IFN-  production by an HLA-A2–restricted NS31406–1415-
specific CD8 T cell clone in response to either four independent HLA-A2  
early (day 5; closed circles and triangles) or late (day 11; open circles and 
triangles) iDC populations cross-presenting either NS3Ag (triangles) or 
peptide (circles). Values represent mean   SD. (B) IFN-  production by an 
NS31406–1415-specific CD8 T cell clone in response to four independent 
HLA-A2  5-d iDCs, 10-d iDCs, or mDCs, which had been unpulsed (dotted 
bars) or pulsed with 50  g/ml NS3Ag alone (closed bars), in the presence 
of leupeptin (hatched bars) or chloroquine (open bars). Values represent 
mean   SD. (C and D) Capacity of PKH67 (green)-dyed 5-d iDCs, PKH67 
(green)-dyed 11-d iDCs (C), or PKH67 (green)-dyed mDCs (derived from 
either 5- or 11-d iDCs; panel D) to phagocytose PKH26 (red)-apoptotic 
cells as detected by FC. Phagocytosis was assessed as DCs double positive 
for apoptotic cells. The numbers of cells in C and D were similar. One rep-
resentative out of three different experiments is shown. (E and F) Surface 
phenotype analysis of 5-d iDCs, mDCs derived from 5-d iDCs (E), 11-d 
iDCs, or mDCs derived from 11-d iDCs (F), in the presence or absence of 
chloroquine. Shaded histograms represent the isotype-matched control 
mAbs; open histograms represent stainings with mAbs specific to the 
surface molecules indicated in the figure. One representative out of three 
different experiments is shown. 
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Figure 4. Improvement of soluble antigen export from endosomes 
into cytosol in chloroquine-treated iDCs. 
 
(A and B) iDCs were pulsed/
chased with either NS3Ag alone or NS3Ag and TRITC-Tf, in the presence or 
absence of chloroquine, fixed, and stained at different times with human 
anti-NS3 alone or with anti-NS3 
 
 
 
 rabbit anti–cathepsin D (C and D), 
followed by staining with the appropriate secondary antibodies. The signal 
of NS3 alone is green. The signals of double staining of Tf or CD and NS3 
are red and green, respectively. The extent of colocalization is shown in 
yellow after merging. Arrows indicate NS3 enrichment or colocalization 
with Tf or CD. In control experiments, DCs were incubated for 1 h at 37
 
 
 
C 
in the presence of 1 mg/ml FITC-dextran with the indicated molecular 
masses and then fixed. One representative out of three different experi-
ments is shown. (C) Quantitative analysis of the fluorescence intensity of 
cytosolic NS3Ag in iDCs pulsed/chased with NS3Ag in the presence or 
absence of chloroquine. (D) Quantitative analysis of the fluorescence 
intensity of cytosolic FITC-dextran in iDCs pulsed/chased with FITC-dextran 
of the indicated molecular masses, in the presence or absence of chloroquine. 
(E) One representative out of three WB analyses on both endocytic- and  
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nose receptors by DCs (unpublished data) (44–47). Thus, the
low cross-presentation efficiency by EBV–B cells could be
caused by their lower antigen uptake capacity, which pre-
cludes the possibility of internalizing the high amounts of
soluble antigens generally required for cross-presentation
(37–40). Control experiments showed that chloroquine im-
proved cross-presentation of soluble NS3Ag in a dose-depen-
dent fashion (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20051106/DC1), which further supports
the data above. In contrast, bafilomycin A1, which increases
the endosomal pH (via its capacity to inhibit the vacuolar
proton ATPase) (48) but not membrane permeabilization
(43), did not improve, but instead inhibited, cross-presenta-
tion by DCs (Fig. S2). Experiments simultaneously per-
formed with those shown in Fig. 1 revealed that cross-pre-
sentation (Fig. 1, A and B) was less efficient than the direct
presentation of NS3Ag, endogenously-synthesized by APCs,
to the same NS3
 
1406–1415
 
-specific CD8
 
 
 
 T cell clone (Fig. 2).
This suggests that endogenous, more than exogenous, solu-
ble antigens have preferential access to proteasome-depen-
dent processing. Further control experiments confirmed
that chloroquine substantially improved cross-presentation
of hepatitis B envelope antigen (HBenvAg) to an HLA-A2–
restricted HBenvAg
 
213–221
 
-specific CD8
 
 
 
 T cell clone by
HLA-A2
 
 
 
 DCs and that lactacystin drastically inhibited
cross-presentation (Fig. S3).
 
Professional APCs are required for cross-presentation 
(and its improvement)
 
iDCs, taken up at day 5 or 10–11 of culture with GM-CSF
and IL-4, maintained similar cross-presentation (Fig. 3, A
and B), stimulation (as detected by their capacity to present
the high affinity HLA-A2–binder NS3
 
1406–1415
 
 peptide; Fig.
3 A), or phagocytosis capacity (Fig. 3, C and D), as well as
surface phenotype (Fig. 3, E and F), over time in vitro (46).
Cross-presentation efficiency was confirmed as being sub-
stantially improved when both early and late iDCs were
pulsed in the presence of chloroquine but not leupeptin (Fig.
3 B). The finding that iDCs were better at cross-presenting
antigens than completely matured DCs (taken up 40 h after
addition of the maturational CD40L stimulus in the iDC
culture; Fig. 3 B) is most likely caused by the low capacity to
internalize antigens via both phagocytosis (Fig. 3, C and D)
and macropinocytosis (as detected by FITC-dextran uptake;
not depicted) of the latter (44–46). Chloroquine did not af-
fect phagocytosis (Fig. 3, C and D) or surface phenotype
(Fig. 3, E and F) by/of DCs, and NS3Ag alone was totally
incapable of inducing DC maturation in vitro (Fig. S4, avail-
able at http://www.jem.org/cgi/content/full/jem.20051106/
DC1), ruling out the possibility that cross-presentation im-
provement was caused by either chloroquine- or NS3Ag-
dependent artifacts. The specificity of cross-presentation was
supported by the finding that the CD8 cell response was
HLA-A2 restricted even when DCs were treated with chlo-
roquine (Fig. S5).
 
Confocal microscopy evaluation of soluble antigen 
trafficking in DCs
 
To support the hypothesis that chloroquine increases the ex-
port of soluble antigens from endosomes to cytosol, NS3Ag
trafficking was evaluated using a confocal laser scan micro-
scope (CLSM) in whole DCs or EBV–B cells. After the ini-
tial 5–15 min of pulsing with NS3Ag, both untreated iDCs
and the chloroquine-treated iDCs revealed colocalization of
NS3Ag with transferrin (Tf )  R (a marker of early endo-
somes; Fig. 4, A and B). After 40 min of chase, the majority
of NS3Ag migrated from TfR
 
 
 
 into cathepsin D
 
 
 
 (a marker
of late endosomes) compartments, and only a tiny part was
exported into the cytosol in untreated DCs (Fig. 4 B). Con-
versely, chloroquine treatment considerably increased
NS3Ag export into cytosol in the later phases, and only a
small amount of antigen was colocalized with cathepsin D in
late endosomes (Fig. 4 B). The magnitude of fluorescence
intensity in cytosolic NS3Ag was much greater in chloro-
quine-treated than untreated DCs, after both 40 and 120
min of chase (Fig. 4 C). In control experiments, DCs were
pulsed with different molecular masses of FITC-dextran.
Dextrans are nondegradable molecules that are internalized
via mannose receptors and transported into cytosol in a size-
dependent fashion (49). Only the 40-kD FITC-dextran, not
the 500 kD, was visualized in the cytosol by confocal mi-
croscopy, irrespective of the presence or absence of chloro-
quine (Fig. 4, A and D). This finding rules out the possibility
that the improvement in cytosolic NS3Ag export was caused
by a trivial endosomal membrane rupture by chloroquine.
Consistent with their incapacity to cross-present, both chlo-
roquine-treated and untreated EBV–B cells showed only a
low NS3Ag export from the endocytic compartments into
the cytosol (Fig. S6, available at http://www.jem.org/cgi/
content/full/jem.20051106/DC1).
 
Biochemical analyses of soluble antigen trafficking in DCs
 
To confirm the evidence that chloroquine favors the export
of soluble antigens from endosomes into cytosol, we per-
formed Western blot (WB) analyses of both cytosol- and en-
docytic-enriched preparations from DCs that had been pre-
 
cytosol-enriched preparations, purified from iDCs, which had been 
previously pulsed/chased (20
 
 
 
/90
 
 
 
) with the indicated concentrations of 
NS3Ag, in the presence or absence of chloroquine. The two preparations 
were then separated by SDS-PAGE and immunoblotted for NS3Ag with 
the relevant human mAb and a secondary peroxidase-conjugated goat 
anti–human IgG antibody. NS3Ag alone (
 
↓
 
) was used as positive control. 
(F) Fluorometric analyses of different FITC-dextrans in endocytic or 
cytosolic fractions from iDCs pulsed with the indicated FITC-dextrans in 
the presence or absence of chloroquine. (G) One representative kinetic 
out of four detected by FC of NS3Ag, TAP-2, or LAMP-2 staining in 
phagosomes containing a mixture of soluble NS3Ag and LB. Analyses 
were performed on gated phagosomes containing LB. Isotype control, 
green; staining after 20
 
 
 
 of pulsing, red; staining after 20’ of pulsing 
 
 
 
 
90
 
 
 
 of chase, blue. 
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viously pulsed/chased with NS3Ag, in the presence or
absence of chloroquine. After 60–120 min of chase, chloro-
quine increased antigen accumulation in both the endocytic
and cytosolic fractions (Fig. 4 E). The chloroquine effect at
the level of the cytosolic fractions was particularly evident at
the lowest antigen concentrations (5 
 
 
 
g/ml) used, which
were visible only in the chloroquine-treated DCs (Fig. 4 E).
In control experiments, the cytosolic and endocytic fractions
derived from DCs incubated with 40- or 500-kD FITC-
dextran, in the presence or absence of chloroquine, were an-
alyzed by a fluorometer. After 1 h of incubation, the 40-kD
FITC-dextran was found in both endocytic and (more im-
portantly) cytosolic fractions in considerably higher amounts
than the 500-kD FITC-dextran, irrespective of the presence
of chloroquine (Fig. 4 F). This finding further corroborates
the interpretation that the greater antigen accumulation in
cytosolic fractions of chloroquine-treated DCs (as detected
by WB analysis; Fig. 4 E) was not determined by an endoso-
mal membrane rupture by chloroquine. In addition, flow
cytometry (FC) analysis was performed on phagosomes iso-
lated from iDCs (50, 51), which had been previously pulsed
and chased with a combination of soluble NS3Ag and latex
beads (LBs) in the presence or absence of chloroquine. In the
early phases, the expression of NS3Ag was substantially
higher in phagosomes from chloroquine-treated DCs, con-
firming that chloroquine also increases antigen accumulation
in early phagosomes (Fig. 4 G). In contrast, chloroquine
treatment did not affect the kinetics of expression of either
phagosomal TAP-2 (as a marker of early phagosomes) (33–
36) or LAMP-2 (as a marker of late phago/endosomes), sug-
gesting that it does not interfere with the phago/endosome
maturation process (Fig. 4 G).
 
Chloroquine elicits antigen-specific CD8
 
 
 
 T cells ex vivo
 
To verify whether chloroquine might expand memory
CD8
 
 
 
 T cell responses ex vivo, PBMCs isolated from three
HCV- (52) and three HIV-infected patients were cultured in
the presence or absence of chloroquine with rNS3Ag or
rNef, respectively, in IL-2–conditioned medium for 15 d.
Under conditions in which PBMCs were first elicited with
NS3Ag in the presence (Fig. 5 A), but not in the absence, of
chloroquine (Fig. 5 B), a noteworthy expansion of CD8
 
 
 
(but not of CD4
 
 
 
) T cells was observed. More important,
CD8
 
 
 
 T cells, which were primarily elicited with NS3Ag in
Figure 5. Chloroquine-boosted cross-presentation elicits antigen-
specific CD8  T cells ex vivo. (A and B) Double CD4 and CD8 FC staining 
in PBMCs from one representative HLA-A2  HCV-infected individual out 
of three studied on 15-d stimulation with NS3Ag in the presence (A) or 
absence (B) of chloroquine. PBMCs were then restimulated (6 h) with 
autologous DCs, which had been pulsed or not as indicated, and tested for 
IFN-  production. The NS31406–1415 peptide was used for detecting the CD8 
cell-dependent IFN-  production, whereas the NS31241–1260 peptide was 
used for detecting the CD4 cell-dependent IFN-  production. (C and D) Double 
CD4 and CD8 FC staining in PBMCs from one representative HIV-infected 
individual out of three studied on 15-d stimulation with 50  g/ml Nef in 
the presence (C) or absence (D) of chloroquine. Cells were then restimulated 
with autologous iDCs, which had been pulsed or not as indicated, and tested 
for IFN-  production. Dot plots are gated on CD8 or CD4 cells and show 
IFN-  staining. Results are expressed as percentages of IFN-   cells and 
are indicated in each quadrant. 
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the presence of chloroquine (Fig. 5 A), produced large
amounts of IFN-
 
 
 
 in response to a secondary stimulation
with the relevant NS31406–1415 peptide plus autologous APCs.
Under these conditions, the generation of antigen-specific
CD4  T cells was completely abrogated. It is noteworthy
that CD8  T cells efficiently responded to a secondary stim-
ulation with the entire NS3Ag only when the latter was
cross-presented by chloroquine-treated DCs (Fig. 5 A).
Meanwhile, stimulation of the NS3Ag-specific CD8  T cell
clone, used in the cross-presentation assays shown in Figs. 1
and 3 and Figs. S1, S2, and S5 above, was already obtained
in steady state cross-presentation conditions and was consid-
erably augmented by adding chloroquine. Furthermore, the
short-term NS3Ag-specific CD8  T cell line, shown in Fig.
5, responded to the same peptide concentration several folds
less than the clone used in the cross-presentation assays (see
Fig. 1 F and Fig. S2). This means that the efficiency of
CD8  T cell stimulation by cross-presentation is not only
dependent on the capacity of APCs to cross-present but also
on the affinity/avidity of CD8  T cells. In contrast, PBMCs,
which were first antigen stimulated in the absence of chloro-
quine (Fig. 5 B), only generated CD4  T cells capable of
recognizing (on a secondary stimulation) both the entire
NS3Ag and the MHC class II–restricted promiscuous
NS31241–1260 epitope. The response of the same antigen-spe-
cific CD4  T cells to a secondary stimulation with the entire
NS3Ag in the presence of chloroquine was strongly inhib-
ited. Comparable results were obtained by Nef stimulation
of PBMCs from HIV-infected patients (Fig. 5, C and D).
Chloroquine elicits antigen-specific CD8  T cells in vivo
Finally, we wondered whether chloroquine might elicit
memory CD8  T cell responses in vivo. PBMCs of healthy
individuals vaccinated with the hepatitis B envelope protein
have been previously shown to contain HBenvAg-specific
CD8  T cells (10, 53, 54). This finding is one of the first to
evidence that exogenous viral proteins can enter the class I
processing pathway (55–58) and that the “class I/II discrimi-
nation” paradigm is not necessarily a rule (59). These data
served as a basis for the experiments reported here, which
were designed to elucidate the role of chloroquine in im-
proving the generation and expansion of HBenvAg-specific
CD8  T cell responses in vivo. Thus, we selected 17 healthy
individuals who had efficiently responded to an anti-HBV
Figure 6. Chloroquine-boosted cross-presentation elicits antigen-
specific CD8  T cells in vivo. ELISPOT assays on fresh CD8  T cells isolated 
from PBMCs of high responders to HBV vaccine, performed before (A) and 
after (B) chloroquine treatment and anti-HBV vaccine boost, or before (C) 
and after (D) only the anti-HBV vaccine boost. Fresh CD8  T cells were tested 
for their capacity to form IFN-  spots within 6 h of contact with autologous 
irradiated APCs, which had been previously pulsed or not with entire 
HBenvAg plus chloroquine or HLA-A2–binding HBenvAg213–221 peptide, in the 
presence or absence of blocking anti-HLA–A,B,C mAb or the corresponding 
isotype antibody, as indicated in A. Results are expressed as spot-forming 
cells (SFC) in 2   105 CD8  T cells. The SFC values were subtracted by back-
ground, which was below 10 SFC in 2   105 cells in each test. SFC values 
obtained in response to the entire HBenvAg were significantly higher in 
chloroquine-treated than in untreated high responders (P   0.001), as well 
as those obtained in response to the HLA-A2–binder HBenvAg peptide 
(P   0.05) calculated among the HLA-A2  high responders. The numbers 
with asterisks represent HLA-A2  individuals. Histograms, attached to the 
right of each panel, report serum anti-HBenvAg (anti-HBs) antibody levels 
determined before and after the anti-HBV vaccination boost in all individuals 
studied (either chloroquine-treated or untreated).CROSS-PRESENTATION IMPROVEMENT BY CHLOROQUINE | Accapezzato et al. 824
vaccination protocol 8–10 yr ago, in terms of both specific
antibody and T cell responses (high responders). In particu-
lar, nine of them received a brief chloroquine treatment per
os, followed by a booster dose of anti-HBV vaccine, whereas
eight underwent the same vaccine boost without the chloro-
quine treatment (controls). The majority of individuals stud-
ied (13/17) were HLA-A2  in order to minimize the possi-
ble diversity of antigen presentation caused by the HLA
polymorphism (Fig. 6). A noteworthy expansion of HB-
envAg-specific effector CD8  T cells was detected by
ELISPOT assay in six of the nine high responders who re-
ceived both chloroquine treatment and the booster dose of
anti-HBV vaccine (Fig. 6, A and B), but was not observed in
the controls (Fig. 6, C and D). The generation of antigen-
specific CD8  T cell responses after the anti-HBV vaccina-
tion boost plus the chloroquine treatment was corroborated
by an efficient CD8  response to the immunodominant
HLA-A2–related HBenvAg213–221 epitope in the HLA-A2 
individuals (Fig. 6, A and B). These data suggest that chloro-
quine can enhance the antigen-specific CD8  T cell re-
sponse to a soluble antigen in vivo. In addition, serum anti-
HBenvAg antibody levels were not affected by chloroquine
treatment (Fig. 6), suggesting that although chloroquine is
not detrimental to the generation of strong antibody re-
sponses, it nonetheless exerts a specific effect on cross-pre-
sentation rather than a general adjuvant effect.
DISCUSSION
The most important finding of this paper is that we demon-
strate for the first time that human CD8  T cell responses
can be efficiently enhanced in vivo with a short course of
treatment with chloroquine followed by a booster dose of a
soluble antigen immunization. Furthermore, we provide ev-
idence that lysosomotropic agents (i.e., chloroquine or
NH4Cl) increase the cross-presentation efficiency in our
model in vitro. The most probable explanation of this find-
ing is that, in the presence of the lysosomotropic agents, in-
ternalized antigens are less efficiently degraded, accumulate
to a higher level in the endosomes, and are ultimately more
efficiently exported into cytosol, as indicated by CLSM and
WB analyses. The finding that cross-presentation was not
enhanced by bafilomycin A1 or various protease inhibitors
supports the hypothesis that the exclusive capacity of the ly-
sosomotropic agents to induce membrane permeabilization
(43), in concert with the capacity to inhibit the endosomal
acidification and, thus, antigen degradation, allows an in-
creased and rapid export of nondegraded antigens from the
endosomes into cytosol. Recent evidences demonstrated
that cross-presentation of soluble antigens that are captured
by DCs via macropinocytosis requires direct delivery into
the perinuclear ER, where they can access the ER-depen-
dent class I processing machinery, precluding their destruc-
tion by endo/lysosomal proteolysis (41). Whether the im-
proved cross-presentation by chloroquine is determined by
increased delivery into perinuclear ER (41) remains an inter-
esting and relevant issue that requires further study. None-
theless, our data highlight that the efficiency of cross-presen-
tation seems directly related to the level of antigen escape
from endocytic processing (60–62). Recently, it has been
suggested that DCs accumulate and process antigens for pre-
sentation to T cells more efficiently than macrophages be-
cause DCs contain considerably lower levels of lysosomal
proteases, which rapidly destroy internalized antigens (63).
However, even if limited, the lysosomal degradation capac-
ity of DCs may be sufficient to restrain cross-presentation of
soluble antigens. This hypothesis is supported by our finding
that chloroquine improves cross-presentation of soluble anti-
gens by DCs and by the well-known evidence that internal-
ization of soluble antigens only results in cross-presentation
at very high concentrations of antigen (11, 12, 14, 15, 28,
38). In contrast, the efficient cross-presentation of particulate
antigens (11, 12, 14, 15, 28, 37) may be explained by the
phagocytosis uptake of particulate antigens being more effi-
cient than fluid-phase uptake of soluble antigens (12, 38, 64).
Alternatively, the evidence that phagosomes export proteins
into the cytosol more efficiently than endosomes may ex-
plain the efficient cross-presentation of particulate antigens
(33–36, 65, 66), which possibly require minimal degradation
(by the partial protease repertoire of DCs [63]) to be cross-
presented (49). This may account for previous observations
reporting that chloroquine did not affect or even inhibit
cross-presentation of particulate antigens (49, 67). The con-
tradictory results between our study demonstrating that
chloroquine enhances CD8  T cell responses against soluble
antigens both in vitro and in vivo in humans and findings
obtained in various mouse models (66, 68) may be partially
explained by differences between human and mouse models
(69) and/or by the different DC populations used. It is diffi-
cult to establish whether chloroquine enhanced antigen-spe-
cific CD8  T cell responses in HBV-vaccinated individuals
in vivo via its capacity to improve cross-presentation, as our
in vitro studies indicated. However, putting together the lat-
ter with the indication that chloroquine reduces protein
degradation in human beings in vivo (70), we are tempted to
hypothesize that the mechanism of chloroquine in our vac-
cination trials might be that of improving cross-presentation
via the inhibition of antigen degradation.
On the basis of data obtained with three different soluble
proteins (NS3Ag, Nef, and HBenvAg), we can, on the other
hand, deduce that the endosomal processing machinery plays
a critical role in limiting cross-presentation of soluble anti-
gens. The endosomal processing machinery may thus repre-
sent a valid checkpoint that contains excessive autoimmune
CD8  T cell responses against soluble self-antigens. In con-
trast, the high cross-presentation efficiency of DCs reported
for particulate antigens will provide either control of infec-
tions or an efficient tolerance toward inert apoptotic cells in
physiological conditions.
Finally, our observations may represent a major break-
through in “vaccinology.” In general, conventional vaccines
(constituted by soluble proteins) used in humans are unable
to prime efficient CD8  T cell responses. The evidence thatJEM VOL. 202, September 19, 2005 825
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chloroquine favors strong CD8  T cell responses in vivo
suggests that it could be exploited for the design of innova-
tive strategies eliciting protective CD8 immunity.
MATERIALS AND METHODS
Antigens. The rNS3Ag1187–1465 expressed in Escherichia coli and affinity puri-
fied was purchased from Biodesign International. The rHBenvAg (ad subtype),
containing the preS115–52, the preS2133–145, and the entire S sequences, was ob-
tained from GlaxoSmithKline Biologicals. The full-length rNef1–206 protein of
HIV-1 was expressed in E. coli and purified as previously described (71).
Cell preparation and surface phenotype. PBMCs were isolated, and
antigen-specific T cell clones were generated as previously described (10).
CD8  cells were purified from PBMCs by positive selection with anti-CD8
mAb coupled to magnetic beads (Miltenyi Biotec). FACS analysis demon-
strated  99% CD8  cells in the positively purified population and  5% in
the CD8-depleted population. iDCs were derived from peripheral mono-
cytes, which had been purified by positive selection with anti-CD14 mAb
coupled to magnetic beads. CD14  cells were then cultured for 5 or 10–
11 d in RPMI 1640 with 5% FCS medium containing 2 mM glutamine, 1%
nonessential amino acids, 1% sodium pyruvate, 50  g/ml kanamycin
(GIBCO BRL), 50 ng/ml GM-CFS (Novartis Pharma), and 1,000 U/ml
rIL-4 (provided by A. Lanzavecchia, Institute for Research in Biomedicine,
Bellinzona, Switzerland). Mature DCs were obtained by a 40-h stimulation
of iDCs with CD40L-transfected J558L cells (DC/J558L ratio   1:1) pro-
vided by P. Lane (University of Birmingham Medical School, Birmingham,
UK), as previously described (13, 46). Both iDCs and mDCs were stained
with anti-CD14, anti-CD86 (Caltag Laboratories), anti-CD32, anti-CD83
(Becton Dickinson), or anti–MHC class I molecule (Serotec, Ltd.) mAbs,
followed by staining with the appropriate secondary labeled antibodies (BD
Biosciences), and were analyzed by a flow cytometer (FACSCalibur; Bec-
ton Dickinson) using CellQuest software (Becton Dickinson).
DC phagocytosis. The phagocytosis capacity of DCs was evaluated ac-
cording to methods described previously (72). In brief, activated T cells (de-
rived from a CD8 clone) were dyed red with PKH26 (Sigma-Aldrich), in-
duced to undergo Fas-mediated apoptosis as previously described (13), and
co-cultured with iDCs or mDCs, which were dyed green with PKH27
(Sigma-Aldrich) at a 1:1 ratio. After 12 h at 4 C or 37 C, phagocytosis was
detected as double-positive cells by FC.
Cross-presentation and antigen stimulation assays. DCs or EBV–B
cells, as APCs, were pulsed with increasing concentrations of soluble anti-
gen or peptide in the presence or absence of 10  g/ml chloroquine,
NH4Cl, leupeptin, 2 ng/ml pepstatin A, 10 mM EDTA, 1 mM peflabloc,
80  M lactacystin (Sigma-Aldrich), or bafilomycin A1 (Qbiogene), fixed
with 0.05% glutaraldehyde (Sigma-Aldrich), and co-cultured with 2–3  
104 cells/well of antigen-specific CD8  or CD4  T cell clones for 6 h at
37 C. At hour 2, 10  g/ml Brefeldin A (Sigma-Aldrich) was added. Cells
were stained with tricolor-labeled anti-CD8 (Caltag) or PE–cyanin 7
(PC7)–labeled anti-CD4 (Beckman Coulter), processed, and analyzed for
detecting the intracellular IFN-  with FITC-labeled anti–IFN-  (BD Bio-
sciences) by FC, as previously described (52). Negative controls were ob-
tained by staining cells with an irrelevant isotype-matched mAb. In some
experiments, the direct presentation of endogenously synthesized NS3Ag to
an NS31406–1415-specific CD8  T cell clone was determined by using 2  
104 autologous EBV–B cells as APCs, which had been infected by either 5
PFU/cell of WT vaccinia virus (VV) or NS3Ag-expressing VV (VV-NS3)
in the presence or absence of lactacystin or chloroquine.
Ex vivo experiments. In the ex vivo experiments, whole PBMCs from
HCV- or HIV-infected individuals were stimulated with 50  g/ml
rNS3Ag or rNef in the presence or absence of 10  g/ml chloroquine. 50
U/ml rIL-2 was added after both 5 and 10 d. After a further 5 d, live cells
were stained with FITC-labeled anti-CD8 (Caltag) and PC7-labeled anti-
CD4 (Beckman Coulter). A tiny fraction of them was promptly analyzed
for both CD4 and CD8 expression by FC. The residual fraction was restim-
ulated with 10  g/ml antigen or peptide and autologous DCs for 6 h and
analyzed for detecting intracytoplasmic IFN-  in both CD4 and CD8 pop-
ulations by FC (52).
In vivo experiments. Of the 17 high HBV vaccine responders selected
for the in vivo experiments, 9 (7 HLA-A2 ) assumed 500 mg per os of
Chloroquine Bayer (Bayer AG), corresponding to a 300-mg base chloro-
quine, followed by a booster dose of anti-HBV vaccine (Engerix-B; Glaxo-
SmithKline) on day 2. As a control, the remaining eight high responders
(six HLA-A2 ) only underwent the booster dose of their regular procedure
of anti-HBV vaccination. The study was performed according to the ethical
guidelines of the 1975 Declaration of Helsinki and a priori approval by our
Institutional Review Board. PBMCs were collected in both groups before
and 10 d after the vaccination booster and tested for the HLA-A2 expres-
sion by FC analysis. CD8  T cells were positively selected from PBMCs
and tested in an ELISPOT assay, as previously described (52), for the IFN- 
spot formation in response to a 6-h stimulation with irradiated autologous
CD8-depleted PBMCs as APCs, previously pulsed or not with rHBenvAg
or peptide, in the presence of chloroquine, blocking anti-HLA–A,B,C mAb
(W6/32, IgG2a; Serotec, Ltd.), or the corresponding isotype. Spots were
quantified using an ELISPOT reader (cod. 99022004; AID GmbH).
Confocal microscopy. APCs were pulsed and chased with 50  g/ml
rNS3Ag alone or together with 50  g/ml tetrarhodamine isothiocyanate–
labeled transferrin (TRITC-Tf; Molecular Probes) in the presence or ab-
sence of 10  g/ml chloroquine for 15 min, washed, and chased for 40 or
120 min at 37 C. They were then fixed with 4% paraformaldehyde, perme-
abilized with 0.1% Triton X-100 in PBS, and stained with different combi-
nations of the following primary antibodies: human anti–HCV-NS31363–1454
mAb (1:100 in PBS; CM3.B6, IgG1) (73) and rabbit anti–cathepsin D poly-
clonal antibodies recognizing the active form (46 kD) of human cathepsin D
(1:50 in PBS; UBI). The primary antibodies were visualized using (a)
FITC-conjugated goat anti–human IgG (1:80 in PBS; Sigma-Aldrich); (b)
Texas red–conjugated goat anti–rabbit IgG (1:50 in PBS; Jackson Immu-
noResearch Laboratories); and (c) Texas red–conjugated rabbit anti–goat
IgG (1:20 in PBS; Sigma-Aldrich). Nonspecific fluorescence was assessed in
control samples by omitting the secondary antibodies from the staining pro-
cedure. In some experiments, DCs were incubated with 1 mg/ml 40- or
500-kD FITC-dextran (Sigma-Aldrich) in the presence or absence of chlo-
roquine at 37 C and fixed. Fluorescence signals were analyzed by recording
staining images using a cooled CCD color digital camera (SPOT-2; Diag-
nostic Instruments Inc.) and IAS 2000/H1 software (Delta Sistemi). Colo-
calization of fluorescence signals was evaluated using a CLSM (LSM 5 PAS-
CAL; Carl Zeiss MicroImaging, Inc.). The multitrack function was used to
prevent cross talk between the two signals. Quantitative analysis of the fluo-
rescence intensity was performed by evaluating three different cytoplasmic
areas (1 mm2 each) per cell in 200 cells for each condition and randomly
taken from three different experiments. The results represent the mean val-
ues   SD. The fluorescence intensity of the control samples was subtracted
from that of the positive-stained samples for each time point.
Purification and FC of phagosomes. DCs were previously pulsed/
chased with a combination of 0.8  m LBs (Sigma-Aldrich) and 50  g/ml
rNS3Ag in the presence or absence of chloroquine. They were then ho-
mogenized, and phagosomes were purified as described previously (28, 34,
50). LB-containing phagosomes were isolated at the 25–10% interface of a
discontinuous sucrose gradient and analyzed by FC as previously described
(51). In brief, LB  phagosomes were fixed and permeabilized using Cyto-
fix/Cytoperm solution (BD Biosciences) at 4  for 20 min and rewashed
with Perm Wash Buffer (BD Biosciences). They were then stained with hu-
man anti-NS3 mAb (73), followed by secondary PE-labeled anti–human
IgG (BD Biosciences) and goat anti–TAP-2 polyclonal antibody (Santa
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ies (Caltag) or mouse FITC-labeled anti–LAMP-2 mAb (Santa Cruz Bio-
technology, Inc.), and analyzed by FC.
Analyses of cytosolic- and endocytic-enriched fractions. To detect
NS3Ag in both cytosolic and endocytic enriched fractions, 10–15   106
DCs were pulsed with different concentrations of rNS3Ag in the presence or
absence of 10  g/ml chloroquine for 20 min, washed, and chased for 90 min
at 37 C. In some experiments, they were pulsed with 1 mg/ml of 40- or
500-kD FITC-dextran for 1 h at 37 C. DCs were then homogenized (49,
50), and the cytosolic and vesicular fractions were isolated as described previ-
ously (49, 50) and analyzed by WB or fluorometer as described below. The
 -hexosaminidase activity (specific to endo/lysosomes), as detected with the
fluorescent substrate 4-methyl-umbelliferyl-N-acetyl–D-glucosamide and
lactate dehydrogenase by measuring the decrease in the absorbance of nico-
tinamide adenine dinucleotide (49, 50, 74, 75), was 10% below that of the
whole cell lysate in the cytosolic fraction (unpublished data). The cytosolic-
and endocytic-enriched fractions, obtained as described above, were sepa-
rated by SDS-PAGE and immunoblotted for NS3Ag with the relevant hu-
man mAb and the secondary peroxidase-conjugated goat anti–human IgG
antibody (Nordic Immunology). Optical density was calculated by the Im-
ageQuanTL software (GE Healthcare). FITC-dextran expression in both en-
dosomic and cytosolic fractions was analyzed using a fluorometer (Wallac
1420 Victor; PerkinElmer Life and Analytical Sciences, Inc.), and values
were computed using the software provided (Victor Manager; PerkinElmer
Life and Analytical Sciences, Inc.). The contents of FITC-dextran were de-
termined from a standard curve of the values of different FITC-dextran con-
centrations. All values were converted into microgram per milliliter ( g/ml).
Statistical analysis. Differences in the cross-presentation assays in the
presence or absence of chloroquine or other drugs (both in vitro and in
vivo) were analyzed by the Mann-Whitney U test.
Online supplemental material. Fig. S1 shows that chloroquine enhances
cross-presentation of NS3Ag by DCs in a dose-dependent fashion. Fig. S2
shows the inability of bafilomycin A1 to improve cross-presentation. Fig. S3
shows the improvement of soluble HBenvAg cross-presentation by chloro-
quine. Fig. S4 shows that rNS3Ag does not affect the surface phenotype of
iDCs. Fig. S5 shows the HLA restriction of NS3Ag cross-presentation. Fig.
S6 shows the inability of EBV–B cells to export soluble NS3Ag from endo-
somes into the cytosol, as detected by CLSM. Online supplemental material
is available at http://www.jem.org/cgi/content/full/jem.20051106/DC1.
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